Investor Center

Investor Center

Corporate Profile

Beam Therapeutics is a biotechnology company committed to creating a new class of precision genetic medicines based on our proprietary base editing technology, with a vision of providing life-long cures to patients suffering from serious diseases.

Recent Press Releases

June 15, 2020
– MGTA-117 conditioning for precise depletion of cells in the bone marrow could potentially increase patients’ benefit from Beam’s base editing therapies for sickle cell disease and beta thalassemia – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 15, 2020-- Magenta Therapeutics (Nasdaq: MGTA) and Beam